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Introduction
Patients with hematologic malignancy (HM) often require
admission to the intensive care unit (ICU) due to organ
failure through disease progression or complications of
treatment. Although there have been improvements in the
prognosis of patients with HM, mortality in this patient
population remains high. We sought to describe patient
characteristics and determinants of outcomes in a Cana-
dian tertiary care setting.
Objectives
To identify prognostic variables and outcomes in patients
with HM who are admitted to the ICU.
Methods
We performed a structured chart review of all adult
patients (age > 18 years) with HM who were admitted to
the ICU of a Canadian tertiary care hospital between
2004 and 2014. Outcome measures included ICU length
of stay, prolonged ICU stay (> 10 days), ICU readmission,
and mortality (ICU, 30-day, 60-day, and 12-month).
A logistic regression model was adjusted for potential
confounding variables and fitted to determine factors
that were predictive of ICU readmission, prolonged ICU
stay, and mortality.
Results
Overall, 206 patients (mean age 51.3 ± 13.6 years; 60%
male) with HM were admitted to the ICU during the
study period. The most common types of HM were acute
leukemia (34.5%) and lymphoma (33.5%). Less than half
(44.7%) of patients had a stem cell transplant prior to
admission. The most frequent ICU admission diagnosis
was respiratory failure (39.8%), followed by hemodynamic
instability (37.9%). The mean ICU stay was 3 ± 6 days,
with 14.1% of patients requiring prolonged ICU stay.
Readmission to the ICU was necessary for 13.1% of
patients. During their ICU course, 71.8% of patients
required mechanical ventilation and 56.8% required vaso-
pressor therapy.
Of patients admitted to the ICU, 45.6% died during
ICU admission, 30-day mortality was 59.2%, 60-day mor-
tality was 62.6%, and 12-month mortality was 74.3%.
After adjustment, factors predictive of mortality in the
ICU were the need for mechanical ventilation (adjusted
estimate [AE] 3.38; 95% CI 1.37, 8.37; P = 0.008) and
need for vasopressor therapy (AE 3.65; 95% CI 1.67, 7.96;
P = 0.001). A surgical procedure was associated with
increased survival (AE 0.21; 95% CI 0.05, 0.86; P = 0.031).
For mortality in survivors of ICU admission, myeloma
was the only significant predictor of 30-day mortality
(AE 0.21; 95% CI 0.06, 0.7; P = 0.011), 60-day mortality
(AE 0.15; 95% CI 0.04, 0.52; P = 0.003), or 12-month
mortality (AE 0.15; 95% CI 0.04, 0.52; P = 0.003).
Conclusions
Over a 10-year period, ICU mortality in patients with
HM was 45.6% and 12-month mortality was 74.3%.
Necessity for mechanical ventilation and vasopressor
therapy were significant predictors of mortality in the
ICU, while myeloma was predictive of longer term
mortality.
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